FDA scolds AbbVie over ‘misleading’ TV ad for a migraine pill featuring Serena Williams

Taking stock of the drug industry, from the lab to the medicine chest

September 11, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Screen capture STAT+ | FDA scolds AbbVie over 'misleading' TV ad for a migraine pill featuring Serena Williams Using a "celebrity athlete" was also problematic because, in this instance, the ad "amplifies the misleading representations, the agency wrote. By Ed Silverman STAT+ | 'Sarepta's like a curse on me': FDA commissioner dismisses controversy over Elevidys FDA commissioner dismissed criticism that the agency is lowering standards for new drug approvals, even when clinical trials fail. By Brittany Trang STAT+ | After FDA rejection, Sanofi and Regeneron's Dupixent succeeds in late-stage trial of chronic hives Results in chronic spontaneous urticaria bring the firms closer to securing FDA approval after the agency rejected their application last year. By Jonathan Wosen Matt Slocum/AP Trump admits he still doesn't have an Affordable Care Act replacement plan Trump's attacks on the popular law create more uncertainty for his party and for the health care industry. By Rachel Cohrs Zhang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser